Clinical knowledge kept current by Hela agents and verified by Hela humans — evidence attached, built for the decisions you make with patients.
Hela agents check every claim against its sources, around the clock. Hela humans — named clinician editors — decide what changes. Structure, context and evidence stay together as medicine evolves.
Hela is named for Helianthus, the sunflower — where every new seed takes its place in the whole.
A condition or a drug, structured into blocks.
The drugs, conditions and criteria it sits between.
Traced to the trials and guidelines it rests on.
A condition or a drug, structured into blocks.
The drugs, conditions and criteria it sits between.
Traced to the trials and guidelines it rests on.
New evidence.
New approvals.
Safer prescribing.
Hela agents find and check. A named clinician reads every change and writes it into the topics it affects. Nothing lands here automatically.
First oral GLP-1 receptor agonist for obesity. Adds a no-injection option; dosing and food-timing rules differ from the weekly injection.
Patent expiry opens supply from more than a dozen Indian manufacturers at a fraction of the originator price. Cost and access notes updated across the obesity, diabetes and PCOS dockets.
SURMOUNT-5: 20.2% vs 13.7% weight loss at 72 weeks in adults with obesity. Drug-choice block updated.
One claim, with the record that keeps it accountable. Every maintained claim in Hela carries the same record.
In adults with PCOS who meet criteria for anti-obesity pharmacotherapy, a GLP-1 receptor agonist may be added to lifestyle intervention, as in the general population. Ensure effective contraception, and stop semaglutide at least two months before a planned pregnancy.
Today — Hela maintains clinical concepts — conditions, drugs, thresholds — with their evidence, review state and version lineage. Hela agents keep every claim checked against its sources; Hela humans — named clinicians — decide what changes.
Toward — a layer other clinical surfaces can build on: EHRs, prescribing tools, patient apps. In progress, not yet live.
Open Hela →
“Medicine moves faster than any one of us can read. Hela exists so that what reaches a patient is the current truth — not last year’s.”
Your intent changes. Your context doesn’t.
Used in type 2 diabetes, chronic weight management, cardiovascular risk reduction and MASH with fibrosis. Delays gastric emptying and reduces appetite. About 15% weight loss at 68 weeks in adults with obesity.
Yes. Semaglutide does not meaningfully change combined-pill exposure. Tirzepatide does — add a barrier method for 4 weeks after starting and after each dose increase. Counsel her to stop semaglutide at least two months before trying to conceive.
| Weeks 1–4 | 0.25 mg |
| Weeks 5–8 | 0.5 mg |
| Weeks 9–12 | 1 mg |
| Weeks 13–16 | 1.7 mg |
| Week 17 on | 2.4 mg |
Hold a step for 4 more weeks if not tolerated. No adjustment for renal or hepatic impairment.
Agents that never stop checking. Clinicians who sign off. A knowledge system for the people who look after patients.